Heart failure & cardiomyopathies
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION Heart Failure (HF)
Authors' conclusion
Incident post-hHF rehospitalization risks and costs were high, and GDMT use changed little in the year following discharge
Study context
- Population
- Adults with a first HF hospitalization discharge, 2018–2022, in Japan, Sweden, UK and US
- Participants
- 263,525 adults
- Outcome
- 1-year death and rehospitalization rates per 100 patient-years after first HF hospitalization
- Follow-up
- 1 year
Methodological detailsmultinational, electronic health records or claims data
- Multinational
- Electronic health records or claims data
Main finding
As reported in the abstract
1 year
Died within first year
28%
Death ER per 100 patient-years
28.4
95% CI 27.0–29.9
HF rehospitalization ER per 100 patient-years
13.6
95% CI 9.8–17.4
CKD rehospitalization ER per 100 patient-years
4.5
95% CI 3.6–5.3
Observational data: associations, not effects.
Further findings
Hospital health care costs
- Costs predominantly driven by HF and CKD
Guideline-directed medical therapy (GDMT) use, 2020–2022
- Uptake of SGLT2 inhibitors increased
- 2- to 7-fold
- Use of RAS inhibitors, sacubitril/valsartan, beta-blockers and MRA changed little
Original publication
Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization: EVOLUTION HF. JACC Heart Fail. Published 21 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →